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Abstract. Globally, scabies affects more than 130 million people at any time. In the developed world, outbreaks in
health institutions and vulnerable communities result in a significant economic burden. A review of the literature demon-
strates the emergence of resistance toward classical scabicidal treatments and the lack of effectiveness of currently avail-
able scabicides in reducing the inflammatory skin reactions and pyodermal progression that occurs in predisposed patient
cohorts. Tea tree oil (TTO) has demonstrated promising acaricidal effects against scabies mites in vitro and has also been
successfully used as an adjuvant topical medication for the treatment of crusted scabies, including cases that did not
respond to standard treatments. Emerging acaricide resistance threatens the future usefulness of currently used gold stan-
dard treatments (oral ivermectin and topical permethrin) for scabies. The imminent development of new chemical entities
is doubtful. The cumulative acaricidal, antibacterial, antipruritic, anti-inflammatory, and wound healing effects of TTO
may have the potential to successfully reduce the burden of scabies infection and the associated bacterial complications.
This review summarizes current knowledge on the use of TTO for the treatment of scabies. On the strength of existing
data for TTO, larger scale, randomized controlled clinical trials are warranted.
SCABIES INFECTION
Epidemiology. Scabies is a contagious, parasitic dermatosis
(skin disease) caused by the acarine itch mite Sarcoptes scabiei
var. hominis, affecting 300 million individuals worldwide each
year, including all age groups and social classes.1–3
A World Health Organization (WHO) review estimated a
global prevalence of 0.2–24%.4 However, the condition is
more prevalent in tropical regions, particularly for pediatric
scabies. In Australia, scabies is a major public health problem
in Indigenous communities, with a prevalence of 25% in adults
and about 30–65% in children.5,6 It is usually contracted by
close, prolonged personal contact with an infected person and
therefore is very common among family members and often
seen in institutional settings.7,8 It is prevalent among young
children and remains frequent in older children and young
adults, possibly due to the absence of immunity and increased
exposure and cross infection between children.9,10
Disease morbidity. Sarcoptes scabiei releases antigens that
diffuse into the outer skin layer resulting in local inflammatory
and immune reactions, leading to severe pruritus and skin
abrasion.11,12 Breaks in the epidermis serve as an entry point
for pathogenic bacteria (usually streptococci or staphylococci),
which complement inhibitors from scabies mites and promote
bacterial growth.13 The scabies mites secrete a number of
endogenous molecules that inhibit the host immune system.13,14
This process is believed to protect the invaded mites from
host defense mechanism. Molecular studies have also revealed
that scabies mites produce a variety of endogenous complement
inhibitors (e.g., scabies mite–inactivated protease paralogues Il
and Dl and scabies mite serpins such as SMSB3 and SMSB4),
which interfere with different stages of host defense compli-
ment cascades and promote the formation of bacterial patho-
gens (e.g., Staphylococcus aureus and Streptococcus pyogenes)
in the patient’s body favoring the establishment of secondary
bacterial coinfections.14–16 Superinfected lesions may develop
into cellulitis or impetigo and may contribute to abscess forma-
tion. These sequelae predispose the infected individuals to sep-
sis and other nonsuppurative invasive infections, as explained
in Figure 1.17 A more severe or “crusted” form of infestation
is associated with extreme incapacity and with disorders of
the immune system, for example, human immunodeficiency
virus infection.
In Australia, the Indigenous population has been found to
suffer from streptococcal septicemia (with infectious diseases
driven by impetigo and associated scabies being the major
cause in rural and remote areas) at a five times greater rate
than the general population.18 This contributes to an estimated
life expectancy gap of 13 years (2012 data) between Indige-
nous and non-Indigenous Australians.19 Furthermore, a clear
link between scabies and bacterial pyoderma has been iden-
tified as the causative factor for rheumatic fever and heart
disease, skin sepsis, and renal disease in Aboriginal and
Torres Strait Islander communities in Australia.20
Economic burden of disease. A 2004 U.S. study estimated
the annual economic burden for scabies management at
US$10.4 million.21 In Australia, the estimated annual (2013
data) cost associated with the management of pediatric scabies
and pyoderma per patient was AU$10,000. This is the mini-
mum cost associated with hospitalizations as no further data
or comprehensive estimates of the annual economic burden
are available.6,22,23
Current treatments. Topical treatments for scabies include
sulfur, benzyl benzoate, allethrin, thiabendazole, crotamiton,
monosulfiram, malathion, lindane, and permethrin. Oral treat-
ments are limited to ivermectin. All scabies treatments are
potentially hazardous and associated with moderate to severe
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side effects (Table 1).2,8,41,45–47 The most frequent complication
of topical scabicides is persisting post-scabies eczema (general-
ized eczematous dermatitis) from the various formulations.12
Further, it may be difficult to treat patients with secondary
eczematization, erosions, or ulcers using topical scabicidal
agents, as they can cause serious cutaneous and systemic
side-effects, resulting in poor treatment uptake.48
Ivermectin (the sole oral treatment) is delivered to the
infective organisms via ingested intraepidermal fluids. Hence,
young children, the elderly (particularly women), individuals
with asteatotic skin (e.g., taking estrogens or retinoids), and
diabetic individuals are at increased risk for treatment failure
due to minimum sebum production.49 No currently available
acaricides for scabies possess ovicidal activity, so re-treatment
is sometimes needed, to kill newly hatched mites. This prob-
lem is further exacerbated by increasing acaricide resistance
leading to treatment failures.50
Acaricide resistance. In vitro and in vivo studies completed
in Australia and elsewhere have raised concerns about increas-
ing resistance to ivermectin (Australian authors reported
strains that were totally resistant to ivermectin) and permeth-
rin.1,31,51–55 A 1994 in vitro study reported 100% mortality of
scabies mites after 1 hour exposure to 5% permethrin; how-
ever, a study conducted 6 years later showed > 3-fold increase
in tolerance to permethrin.1,7,50,56 More recent studies have
confirmed that permethrin is now the slowest acting acaricide
in vitro in this region (Northern Territory, Australia).50 A
2013 review article cited seven incidents of ivermectin resis-
tance leading to treatment failures in northern Australia.7
Clinical and in vitro ivermectin resistance has also been docu-
mented in crusted scabies patients.7 In vitro sensitivity data
from the past 10 years indicate that median survival times for
ivermectin have doubled since its introduction.56 A 2009 clini-
cal trial in Senegal reported poor therapeutic response to
ivermectin for the management of scabies in children. There
was a cure rate of 24.6% with a single dose of ivermectin
150–200 μg/kg, although the study has been criticized for the
variability of dose administered. The authors have also now
indicated the possibility of ivermectin resistance in the treated
patient cohort resulting from the previous use of ivermectin
in the mass treatment program for onchocerciasis, a parasitic
disease also known as river blindness caused by filarial worm
Onchocerca volvulus.57 Further, when ivermectin is used
alone, it is not effective against crusted scabies, requiring
coadministration of topical agents such as scabicidal prepara-
tions or keratolytics. In addition, resistance to other acari-
cides, such as lindane and crotamiton, has also been reported
worldwide.1,3,7,46,56,58
An ideal acaricide would possess ovicidal, antibacterial,
anti-inflammatory, and/or antipruritic properties, and would
be effective in preventing treatment relapse (resulting from
newly hatched mites), inflammatory skin reactions (from mite
antigens), and pyodermal progression. It would have a low
incidence of resistance and would not contribute to the
development of resistance to other agents. The long-term use-
fulness of ivermectin and permethrin for the treatment of sca-
bies is uncertain because they fail to meet these requirements.
It is doubtful that new chemical entities will be developed in
the near future. Though there may be potential for immuno-
logical control, the development of a vaccine may be decades
away.7 Veterinary vaccines are available (e.g., TickGARD,
GAVAC) for the management of ectoparasitic conditions such
as cattle tick (Boophilus microplus).59 Development of a
scabies vaccine seemed feasible, since animals that recover
from the infection possess protective immunity against mite
reinfestation.60–62 Vaccination using dust mite extracts provided
protection for immunized animals from mite challenge63;
however, several obstacles have hindered development of a
scabies vaccine.63 Further studies are required to identify the
protective antigens and/or antibodies, and deliver a detailed
understanding of how the body’s immune system controls
scabies, including increased understanding of immune patho-
genesis of crusted scabies.63 Preexisting immune responses to
selected antigens in endemic areas (e.g., indigenous commu-
nities in Australia) also need careful consideration.63,64 Com-
pliance to vaccination could be a potential limiting factor in
community settings; latest advancements in the field such as
needle-free skin vaccination could be an attractive option to
administer vaccine in mass immunization programs to eradi-
cate this highly debilitating infection.63,65
Another important consideration is that patients with crusted
scabies are often identified as core transmitters of scabies to
others in the community, and therefore the spread of acaricide-
resistant mites may jeopardize the future of current treatment
FIGURE 1. Complications of scabies infection, modified from Engelman and others.3
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options.58,66 There is clearly a need for further clinical stud-
ies to assess alternative treatments that have shown excellent
results in preliminary in vitro studies. Botanicals have been
identified for the management of infectious skin conditions
and a partial summary of the key candidates is summarized
in Table 2.67,68 This topic has been extensively reviewed and
updated in recent publications.68,69 Of these botanicals, tea
tree oil (TTO) is an ideal candidate for research.1
TEATREE OIL
TTO is documented as having been used in the community
(in Australia and internationally) for over 90 years.70,71 Indig-
enous populations have been using this plant, Melaleuca
alternifolia, and derivatives for far longer. TTO has been
found to be effective (in vitro) as a bactericide (at 0.002–2%;
including against MRSA [methicillin-resistant S. aureus]),
fungicide (0.004–0.25%), and as an anti-inflammatory agent
(≤ 0.125%).70,71 It has been used in reducing MRSA coloniza-
tion and in the treatment of a wide range of bacterial, fungal,
and viral skin infections. It has also been used as a topical
antipruritic agent.70–72 The therapeutic benefits of TTO-
containing formulations for a range of dermatological condi-
tions have been investigated in several randomized controlled
trials (RCTs), which have demonstrated safety and efficacy
in the general population (noted studies are summarized
in Table 3).70,71 Levels of components in TTO are specified
under an International Organization for Standardization stan-
dard (ISO 4730), reducing the potential for compositional var-
iation, which is often noted as a problem with botanical
medicinal products.70,71
Antibacterial activity. The potent antibacterial activity of
TTO has received much attention, highlighting its potential
usefulness as a topical antibacterial agent.70,71 Minimum
inhibitory concentrations (MICs) range from approximately
0.06–0.5% for a wide range of gram-positive and gram-negative
bacteria, with the exception of Pseudomonas aeruginosa,
which has MICs in the range of 2–8%.75 Of note is that TTO
is equally active against antimicrobial resistant and susceptible
strains, such as MRSA and methicillin-susceptible S. aureus.
Anti-inflammatory activity. Terpinen-4-ol, at concentrations
equivalent to 0.125%, can inhibit the production of several
inflammatory mediators, such as tumor necrosis factor alpha,
interleukin-1β, and prostaglandin E2, as well as superoxide pro-
duction, resulting in diminished inflammatory response.70 TTO
has been shown to reduce hypersensitivity responses in the skin
including responses to insect bites, bee stings, hives, and metal-
induced hypersensitivity.76 This is chiefly attributed to the
ability of TTO to modulate the vasodilation and plasma extrav-
asation associated with histamine-induced inflammation.77
Application of the topical scabicide benzyl benzoate is typi-
cally associated with a burning sensation, and in children it needs
to be diluted to reduce the severe stinging sensation. Dilu-
tion compromises its potency and efficacy. The incorporation
TABLE 2
A partial summary of various plant-derived treatments used for the management of infectious dermatological conditions
Botanicals Pharmacological claims
Achyranthes aspera (Amaranthaceae) Traditionally used for the management of scabies
Allium cepa (Liliaceae) Management of fungi-associated skin diseases
Aloe vera (Xanthorrhoeaceae) Antibacterial and antifungal properties
Arborvitae (Thuja occidentalis; Cupressaceae) Treatment of verruca vulgaris
Beard lichen (Usnea barbata; Parmeliaceae) Antibacterial activity against gram-positive bacteria
Cannabis sativa (Cannabaceae) Crushed leaves used for the management of scabies
Celandine (Chelidonium majus; Papaveraceae) Treatment of warts
Coriandrum sativum (coriander oil; Apiaceae) Antibacterial properties; treatment of inflammatory
skin conditions with bacterial colonization
Echinacea purpurea, Echinacea angustifolia (Asteraceae) Traditional oral remedies for warts
Epigallocatechin gallate (standard green tea extract; Theaceae) Management of external genital or perianal warts
Eucalyptus globulus (Myrtaceae) Management of facial demodicosis
Eucalyptus pauciflora (essential oil of snow gum; Myrtaceae) Strong antifungal activities against a broad-spectrum
funding including dermatophytes
Euphorbia wallichii, Euphorbia hirta, Euphorbia tirucalli (Euphorbiaceae) Activity against gram-positive bacteria and fungi
Ficus carica, Ficus racemosa, Ficus benghalensis (Moraceae) Management of warts and scabies
Garlic (Allium sativum; Amaryllidaceae) Key active ingredient (ajoene) possess antifungal properties
Hyperforin (Hypericum perforatum [Saint John’s wort]); Clusiaceae) Antibacterial activity against gram-positive bacteria
Japanese herbal medicine (Kampo medicine) Antibacterial against Propionibacterium acnes,
Staphylococcus epidermis, and Staphylococcus aureus
Lawsonia inermis (Lythraceae) Treatment of impetigo
Lemon balm (Melissa officinalis; Lamiaceae) Antiviral properties
Leptospermum scoparium (Myrtaceae) Antibacterial, antifungal, and anti-inflammatory properties
Mangifera indica (Anacardiaceae) Treatment of scabies
Melaleuca alternifolia (tea tree oil; Myrtaceae) Antibacterial, antifungal, and antiparasitic properties
Olibanum (Boswellia serrata; Burseraceae) Antibacterial activity against gram-positive bacteria
Plumbago zeylanica (Plumbaginaceae) Treatment of ringworm
Podophyllotoxin (Podophyllum peltatum; Berberidaceae) Management of condyloma acuminata (anogenital wart)
Rosmarinus officinalis (rosemary oil; Labiatae) Antibacterial activity against gram-positive bacteria
Sage (Salvia officinalis; Lamiaceae) Antibacterial activity against gram-positive bacteria
Sarcococca (Caesalpiniaceae) Treatment of scabies and tinea pedis
Siberian ginseng (Eleutherococcus senticosus; Araliaceae) Traditional oral remedies for warts
Melaleuca alternifolia (Myrtaceae) Activity against bacterial, viral, fungal, and protozoal
infections affecting skin
Thyme vulgaris (Lamiaceae) Treatment of bacterial skin infections
Adapted from References.67,68
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of TTO (5%) into a commercial product (Ascabiol®, 25%
benzyl benzoate) has been found to improve the tolerability of
the product, chiefly attributed to the anti-inflammatory activity
of TTO components.50,78
Antipruritic activity. TTO has also demonstrated benefit
in reducing pruritus in human and animal studies.72,79–81
However, large scale RCTs to further explore the antipruritic
efficacy of TTO-containing formulations have not been
performed. Sufficient anecdotal evidence exists to warrant
comparing TTO formulations against active comparators for
the therapeutic management of pruritic skin conditions.
PRELIMINARY DATA/PILOT STUDIES
Insecticidal, acaricidal, and repellent effects of TTO. TTO
has shown insecticidal, acaricidal, and repellent effects against a
range of medical and veterinary pests when compared with com-
mercial preparations both in vitro and in vivo, including white-
fly,82 head lice (Pediculus humanus var. capitis),73 and sheep lice.83
Acaricidal effects. In addition to its broader insecticidal
activity, TTO has also demonstrated promising potential as
an acaricide in numerous in vitro and in vivo exploratory
studies. House dust mites (Dermatophagoides pteronyssinus)
showed 100% mortality in vitro after exposure to a 10%
TTO formulation.84 Face mites (Demodex folliculorum) sur-
vived only 3.7 minutes after in vitro treatment with 100%
TTO, and 14.8 minutes after 50% TTO compared with no
mortality at the maximum observation time of 150 minutes
after treatment with 10% povidone iodine or 4% pilocar-
pine.85 In an in vivo trial using a daily eye-lid scrub containing
50% TTO, there was a 78% cure rate (N = 7/9) at 4 weeks
and no recurrence 1 month later85,86; Swine mange mite
(S. scabiei var. suis) infestation was resolved in 98.5% of cases
4 weeks after treatment completion in an in vivo field trial
using two applications of 1% TTO a week apart.87 The
in vitro scabicidal activity of TTO against human scabies
mites, S. scabiei, demonstrated a superior result in compari-
son with standard treatments (150 minutes with ivermectin
100 μg/g; 120 minutes with permethrin 5%, compared with
60 minutes median survival time with 5% TTO).1,78 TTO
5% has also been used on an ad hoc basis at the Royal Darwin
Hospital (Darwin, Northern Territory, Australia) in combi-
nation with benzyl peroxide and oral ivermectin (200 μg/kg)
for the management of complicated crusted scabies (two to
three times per week for 1–4 weeks, depending on the disease
severity)88 and in patients who did not initially respond to oral
ivermectin therapy.1
Safety, tolerability, and stability. Topical application of
TTO is associated with a low incidence of adverse effects,
mostly irritant or allergic reactions to the oil. Irritant reactions
can be largely avoided through the use of products containing
lower concentrations of oil. Although the threshold for irritant
reactions has not been determined, it seems they are rarely
associated with TTO concentrations less than 20%. When the
oil was formulated in a suitable pharmaceutical base (cream/
ointment/gel) containing concentrations of 25% or less and
was applied once daily for 21 consecutive days (N = 311,
adults), it caused no skin irritation.89 Allergic reactions may
occur even at very low concentrations and can be confirmed
using patch tests. The incidence of positive patch tests to
TTO in consecutive patch-tested patients attending specialist
dermatology or immunology clinics is approximately 0.03%.90
Another study, in which 217 patients from a dermatology clinic
were patch tested with 10% TTO, found no irritant reactions.91
The potential for TTO toxicity in children is yet to be eval-
uated extensively. A recent RCT investigated the use of TTO
(75%) for the management of the viral infection molluscum
contagiosum in children (mean age = 6.3 + 5.1 years, 30 days
treatment).92 TTO was found to be well tolerated in the
treatment cohort. Another study showed that the irritation
potential of TTO resulted from the oxidation of oil leading to
elevated levels of peroxide and 1,2,4- trihydroxy menthane.93
1,2,4-Trihydroxy menthane is a degradation product of TTO
and a known skin sensitizer.94 Neat TTO is sold in amber
glass bottles fitted with child-resistant polypropylene caps and
is recommended to be stored at 22°C away from direct heat
TABLE 3
Selected randomized controlled trials of TTO in dermatology
Author, year, origin, design Population and size Results
Enshaieh and others, 2007,
Iran, RCT
N = 60, 15–25 years with mild
to moderate facial acne
The treatment group (5%, TTO gel) was 5.8 times
more effective than placebo (P > 0.05)
Carson and others, 2001,
AUS, RCT
N = 16, 18–70 years with a self-reported
history of recurrent herpes labialis
In the treatment group (6% TTO gel), median time
for reepithelialization was 9 days vs. 12.5 days for
placebo (P > 0.5)
Satchell and others, 2002,
AUS, RCT
N = 126, 14 years and above with mild
to moderate dandruff
5% TTO shampoo showed a 41% improvement in
the severity score compared with 11% in the
placebo group (P < 0.001)
Dryden and others, 2004,
AUS, RCT
N = 236, adults colonized with MRSA TTO preparations (10% cream, 5% body wash) were
more effective than chlorhexidine or silver sulfadiazine
at clearing skin lesions
Tong and others, 2007,
AUS, RCT
N = 121, adults with clinically diagnosed
tinea pedis
Mycological cure rate was 64% in the 50% TTO group
compared with 31% in the placebo group
Barker and others, 2010,
AU, RCT
N = 123, children 4–12 years infested
with live head lice
The pediculicide-containing TTO and lavender oil
(10% TTO and 1% lavender oil) showed 97.6%
effectiveness (louse-free subjects) as opposed to 25.0%
by the commercial product containing pyrethrins
(1.65 mg/g) and piperonyl butoxide (16.5 mg/g)
Blackwood and others, 2013,
Ireland, RCT
N = 445, adults admitted to intensive
care facilities
TTO (5%) group showed no difference (P > 0.5) to
standard care (Johnson’s Baby Softwash) in preventing
MRSA colonization
AUS = Australia; MRSA = methicillin-resistant Staphylococcus aureus; TTO = tea tree oil.
Adapted from Carson and others,70 Barker and others,73 and Blackwood and others.74
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and light. In typical in-use conditions, TTO will have no
appreciable degradation for up to 12 months.89,93
The chemical composition of TTO has been widely studied
and well defined. TTO consists largely of cyclic monoterpenes,
of which about 50% are oxygenated and 50% are hydrocar-
bons.95 The international standard ISO 4730 for Melaleuca,
terpinene-4-ol type (TTO) contains three major components:
terpinen-4-ol, γ-terpinene, and α-terpinene comprising about
70% of whole oil, while ρ-cymene, terpinolene, α-terpineol,
and α-pinene account for about 15% of the oil.95,96 Because
of high volatility, 90% of the TTO is removed quickly from
the skin surface, minimizing the potential for TTO components
to travel into the deeper layers of the skin and to be absorbed
into the bloodstream.97 Under nonoccluded conditions, pene-
tration of TTO components through the skin is limited but
terpinen-4-ol and α- terpineol (the chief bioactive constitu-
ents96,98) are able to penetrate the epidermal layer (3.6–8.0%
and 3.6–8.4% of the applied amount, respectively, over 25-hour
period after application of the pure oil97) of the skin suffi-
ciently to provide antimicrobial, anti-inflammatory, and acari-
cidal effects.70,99 However, when 20% TTO formulation (in
ethanol) was tested, only terpinene-4-ol (< 0.05% of the applied
formulation) was able to fully penetrate the epidermis.97
Resistance to TTO. Since its introduction in the 1920s,
resistance to TTO per se has not yet been reported. It has
been postulated that the multiple active components in TTO
may reduce the potential for resistance to occur spontaneously,
since multiple simultaneous mutations would be required to
overcome all the actions of the individual components.70 TTO
is known to affect multiple properties and functions associated
with the cell membrane (similar to membrane-active biocides),
meaning numerous targets would have to adapt to overcome
the effects of the oil.70
DISCUSSION
Scabies was listed as a neglected tropical disease by the
World Health Organization (WHO) in 2013.100 Preventing
and decreasing morbidity associated with scabies infestation is
a national public health priority in some countries. WHO has
called for an international alliance for research into the con-
trol of scabies. In the developed world, outbreaks in health
institutions and vulnerable communities result in a significant
economic burden.17 In 2010, it was estimated that the direct
effects of scabies infestation on the skin alone led to more
than 1.5 million years lived with disability, and the indirect
effects of complications on renal and cardiovascular function
were found to be far greater. The antibacterial properties,
together with wound healing effects,101,102 of TTO could pre-
vent the disease progression to pyoderma, secondary sepsis,
and other suppurative and nonsuppurative bacterial complica-
tions associated with scabies infestation, especially in children.
Furthermore, the anti-inflammatory and antipruritic activity of
TTO could reduce the inflammatory immune reactions seen
as a response to mite antigens.
Preclinical investigations have demonstrated superior
scabicidal properties of TTO when compared with widely
used scabicidal agents, such as permethrin 5% cream and
ivermectin. Hence, it is reasonable to assume that a TTO-
containing formulation (≥ 5%) could be useful for the man-
agement of scabies infestations in humans and would be
less likely to cause cutaneous and/or systemic side effects.
Intuitively, this approach could lead to the development of
a topical treatment option for the therapeutic management
of ectoparasitic infestations in humans and in animals (“one
health approach”). TTO formulated for topical use would
have the added advantage of being cost-effective, simple to
use, and could be implemented in remote communities as a
traditional medicine for the long-term management of sca-
bies and pyoderma in children.
Despite the fact that TTO has a relevant spectrum of
activity against scabies’ mites, proven antimicrobial and anti-
inflammatory activities, putative anti-itch properties, and prom-
ising preliminary clinical evidence of safety and effectiveness,
it is unlikely to be investigated and developed as a treatment
of scabies by the usual commercial mechanisms. This is
because the intellectual property associated with these prop-
erties is already in the public domain and TTO would not
meet the novelty requirement for a patent. Although patents
are not the only mechanism that may be used to protect
intellectual property, they are a cornerstone of the commercial
drug development process.103 Without a patent or other simi-
lar means to protect the intellectual property associated with
developing and using TTO to treat scabies, there is little com-
mercial incentive for anyone to bear the risk and cost associ-
ated with product development and safety and efficacy testing.103
Consequently, the evaluation of a potentially useful, low-cost,
nonproprietary treatment may continue to be overlooked.
Ironically, the burden of scabies disease is borne dispropor-
tionately by the poor,104 a group likely to benefit the most from
the availability of nonproprietary treatments such as TTO.
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